2026 AAHKS Annual Meeting: Addition of Suzetrigine to a Multimodal Pain Pathway Reduces Opioid Use In Total Knee Arthroplasty

255 patients undergoing primary total knee arthroplasty (TKA) were retrospectively evaluated after receiving standard multimodal pain management (n=184) or multimodal pain management supplemented with suzetrigine (n=71). The primary outcomes of interest were postoperative opioid consumption and pain reduction. Secondary outcomes included complete opioid avoidance, independent ambulation, manipulation under anaesthesia (MUA), emergency department (ED) visits for constipation, and treatment-related complications. Outcomes were assessed postoperatively, with independent ambulation evaluated at 4 weeks. Overall, the results revealed that adding suzetrigine significantly reduced opioid consumption and postoperative pain while increasing opioid avoidance and improving early mobility. These findings suggested that suzetrigine may be an effective non-opioid addition to multimodal analgesia following TKA.